Portfolio company PathoQuest (NGS-based biosafety) announced acquisition by Charles River Laboratories.
PathoQuest provides a validated Next Generation Sequencing (NGS) approach in biosafety testing, biopharmaceutical characterization, and release for global companies and emerging biopharma companies
PathoQuest provides a validated Next Generation Sequencing (NGS) approach in biosafety testing, biopharmaceutical characterization, and release for global companies and emerging biopharma companies. Their iDTECT® platform offers GMP validated NGS bioassays for viral safety and genetic characterization.